Leavitt
Lack of data makes it hard to assess 340B's impact on drug company launch prices and covered entities' uses of 340B savings, researchers at consulting firm Leavitt Partners say.

Extent of 340B’s Impact on Overall Drug Prices Unclear Due to Lack of Data, Study Finds

Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.

“We found compelling evidence that the 340B program does impact how pharmaceutical manufacturers set list prices for drugs and the drug prices covered entities charge patients and various payors,” the researchers said in the Dec. 1 white paper.

Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts